Xavier Gitton

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

Helen J. Lachmann, Isabelle Koné‐Paut, Jasmin Kuemmerle‐Deschner et al. · New England Journal of Medicine · 2009 · 858 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

Thomas J. Schnitzer, Gerd R Burmester, Eduardo Mysler et al. · The Lancet · 2004 · 702 citations

Medicine, Pharmacology, Pharmacotherapy +15

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

Michael E. Farkouh, Howard S. Kirshner, Robert A. Harrington et al. · The Lancet · 2004 · 490 citations

Medicine, Pharmacology, Pharmacotherapy +13

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

Rieke Alten, Juan J. Gómez‐Reino, Patrick Durez et al. · BMC Musculoskeletal Disorders · 2011 · 151 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Evaluation of the Patient Acceptable Symptom State in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis

Maxime Dougados, Alan Moore, Shaohua Yu et al. · Arthritis Research & Therapy · 2007 · 56 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14